- $74.16m
- $77.72m
- $0.03m
Annual balance sheet for Impact Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.046 | 0.002 | 0.001 | 2 | 0.003 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.197 | 0.016 | 0.331 | 0.184 | 0.203 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 0.287 | 0.122 | 0.332 | 2.45 | 0.411 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 0.276 | 0.287 | 0.017 | 0 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 56.4 | 46.5 | 44.6 | 20.3 | 17.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 12.6 | 10.6 | 13.1 | 9.79 | 1.16 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Liabilities | 19.8 | 16.9 | 19.4 | 16 | 4.8 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 36.6 | 29.6 | 25.2 | 4.26 | 12.6 |
| Total Liabilities & Shareholders' Equity | 56.4 | 46.5 | 44.6 | 20.3 | 17.4 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |